Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of ACYW135 meningococcal conjugate vaccine immunogenicity and safety in healthy participants aged 2-55 years
ChiCTR2200058397Phase 3Not yet recruiting
- Sponsor
- Shaanxi Provincial Center for Disease Control and Prevention
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Meningococcal ACWY conjugate vaccine in meningococcal disease (6 arms), sponsored by Shaanxi Provincial Center for Disease Control and Prevention. Primary endpoints: Group W135 meningococcal serum bactericidal activity antibody, Group A meningococcal serum bactericidal activity antibody and 2 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
Meningococcal ACWY conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on ChiCTR2200058397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058397.